Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
I would very much hope the Notice Of Interims RNS will arrive this week and the Results themselves, next week.
One positive I’m fully expecting (not hoping), is that regardless of the stated progress of all clinical trails, there have been no significant safety related issues to this point in time in 2024. If there were, then they surely would have been reported by now.
One critical positive “in the bag” I would suggest, in terms of what happens as 2024 pans out.
Perhaps the IC article will bring new investors in…………
https://www.investorschronicle.co.uk/ideas/2024/01/15/a-harsh-market-reaction-to-ramsdens-record-full-year-profits/
I suspect it’s also the case that some of those selling aren’t just Traders, they are Investors who don’t see any short-medium term inflection points ie. they expect the SP to just bumble along sub 225p for the rest of the year and want to place their bets elsewhere.
Clearly I didn’t describe it as chaff, nor did I make any attempt, or suggestion, that it shouldn’t be read. Crystal clear.
For me though, the content of the Interims are far more important in connection with my investment here. Just a couple of weeks away, assuming on schedule.
Jackdaw - the critical point I’m making, is not at all that the Interims will be the latest news, when issued, more that they will be official news from a known source ie. the Company. Don’t know about you but I’ll place more of my investment decision around that.
Not against reading other material, if clearly relevant to Scancell, context provided and not just chaff lifted from the web (not suggesting this is the latter).
Can understand the disappointment that the SP is where it is. After all, we’re all here to make a profit on the Share.
However, I don’t see any part of last year as a fiasco and am pretty sure many invested here would agree. As a for instance, for anyone bemoaning the “low Genmab payment”, there are others who see that as a significant step forward for the Company.
Perhaps you should “go check the Forum” to see those alternative views.
Annual Results 15th Jan then and will reveal if PBT is above the £10M anticipated by the Board. Something closer to £10.5M would perhaps be a catalyst for the SP, particularly if accompanied by a bullish outlook statement.